NCT07081633

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

An Open-label, Multi-center Phase II Study of Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 114 (estimated)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Durvalumab	Durvalumab IV (intravenous infusion)
DRUG	Tremelimumab	Tremelimumab IV (intravenous infusion)
COMBINATION_PRODUCT	Lenvatinib	Lenvatinib Oral

Timeline

• Start date: 2025-08-05
• Primary completion: 2026-11-30
• Completion: 2028-12-31
• First posted: 2025-07-23
• Last updated: 2025-12-30

Locations

24 sites across 2 countries: China, Hong Kong